Dino. Glad you're seeing some green. You've hung around a lot longer than I. Taking a profit is never bad. I do however see some upside here. This company is taking fairly common drugs, that are already approved by the FDA. If they can put it in eye for three years and see real upside no down, they just may have something. Similar technology is already approved and effective and COMPLETELY THIERS; they have two approved platforms. Look at Pfizer and the new deal. Lotanoprost is approved and went Generic. This drug is effective and administered as a topical; compliance is a problem. The market for this expired drug is gone for PFE. But, could the delivery of the same drug directly on location be more beneficial? I believe it can and will, so doe's PFE, hence; the new trial with PFE paying the bill. Pfizer, paying the bill and giving PSDV a nice 2MIL bonus, plus a 20% profit sharing.That's all good for this little micro cap. They have two more bio-erodible platforms. If you can afford it, hold it awhile.It will move up several bucks up for sure, before November . Pretty soon many big Pharma's will find PSDV very attractive. I think it's PFE right after approval........but then I am drinking beer. Good Luck.